Home » Stocks » YMTX

Yumanity Therapeutics, Inc. (YMTX)

Stock Price: $19.90 USD -0.32 (-1.58%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 197.66M
Revenue (ttm) 3.31M
Net Income (ttm) -38.80M
Shares Out 2.61M
EPS (ttm) -15.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $19.90
Previous Close $20.22
Change ($) -0.32
Change (%) -1.58%
Day's Open 20.18
Day's Range 19.51 - 20.18
Day's Volume 34,801
52-Week Range 0.89 - 22.52

News

Hide News
GlobeNewsWire - 2 weeks ago

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modif...

GlobeNewsWire - 4 weeks ago

Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020

About YMTX

Yumanity Therapeutics discovers and develops disease-modifying therapies for neurodegenerative diseases. It focuses on discovering disease-modifying therapies for patients with Parkinson's, amyotrophic lateral sclerosis, and Alzheimer's diseases. The company concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. Yumanity Therapeutics Inc. has a strategic research collaboration and license agreement with Merck. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
IPO Date
Feb 11, 2016
CEO
Meenu Chhabra
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
YMTX
Full Company Profile

Financial Performance

In 2019, YMTX's revenue was $5.00 million, an increase of 76.06% compared to the previous year's $2.84 million. Losses were -$59.13 million, -4.38% less than in 2018.

Financial Statements